Medical Cannabis and Mental Health UK — What Patients Need to Know

Mental health conditions are among the most common reasons UK patients seek a private medical cannabis prescription. Anxiety disorders, PTSD, and depression feature prominently in prescription data. However, the relationship between cannabis and mental health is more nuanced than for purely physical conditions — and it is essential that patients have an accurate, balanced picture before making treatment decisions.

What Conditions May Qualify

Anxiety Disorders

Generalised anxiety disorder (GAD), social anxiety disorder, and panic disorder are among the anxiety conditions for which UK clinics routinely prescribe. The evidence base is meaningful: CBD has established anxiolytic properties and does not carry the anxiety-inducing risk that high doses of THC can present. Clinical data suggest that CBD-dominant or balanced formulations can reduce anxiety symptoms in patients who have not responded adequately to standard treatments — typically SSRIs, SNRIs, or CBT. See our anxiety condition guide for more detail.

PTSD

Post-traumatic stress disorder has among the strongest evidence bases of any mental health condition for medical cannabis. The endocannabinoid system is involved in fear memory extinction — the process by which traumatic memories lose their intensity — and cannabinoids appear to facilitate this process. UK data from Project Twenty21 included PTSD patients and showed meaningful improvements in quality of life and sleep scores. International evidence from Canada and Israel is more extensive and broadly positive. See our dedicated PTSD condition guide for more detail.

Treatment-Resistant Depression

Depression as a standalone primary indication is less commonly prescribed for in the UK than anxiety or PTSD. Treatment-resistant depression presenting alongside other qualifying conditions — chronic pain, anxiety, PTSD — may be considered. The evidence for cannabis as a primary antidepressant is limited and mixed; CBD may have some mood-modulating effects, but this is not an established primary indication at UK clinics.

ADHD

Some patients report symptomatic benefit from cannabis for ADHD, particularly for associated anxiety and sleep difficulties. A small number of UK clinics will consider ADHD as a qualifying condition. The evidence base is limited and the clinical approach varies significantly between providers.

What Does Not Qualify — Conditions Where Cannabis Is Contraindicated

This section is critical. Cannabis is not appropriate for all mental health patients, and prescribing to unsuitable candidates can cause serious harm.

Psychosis and Schizophrenia Spectrum Disorders

Active psychosis is an absolute contraindication to THC-containing cannabis products. THC can trigger acute psychotic episodes, worsen existing psychotic symptoms, and accelerate the clinical course of schizophrenia spectrum conditions. Even in patients with a personal or family history of psychosis, THC carries significantly elevated risk. The association between high-potency cannabis and first-episode psychosis is one of the most well-established findings in psychiatric epidemiology. UK clinics conduct mandatory screening for personal and family history of psychosis before prescribing. No reputable UK clinic will prescribe THC-containing products to a patient with active psychosis.

Bipolar Disorder

Evidence is mixed. Some patients with bipolar disorder report symptomatic benefit; others experience destabilisation of mood — including triggering manic or hypomanic episodes. UK clinics vary in their approach: some will consider prescribing under close monitoring for stable patients with bipolar II; others decline as a policy. If you have bipolar disorder, discuss this explicitly with your clinic before proceeding.

Active Substance Use Disorders

A history of cannabis use disorder requires careful clinical evaluation. It does not automatically disqualify a patient, but responsible prescribers will consider this carefully. Active heavy recreational cannabis use alongside a medical prescription is not appropriate and should be disclosed at consultation.

CBD vs THC for Mental Health

For mental health conditions specifically, the distinction between CBD and THC is more clinically significant than for many physical conditions:

• CBD: Non-psychoactive, anxiolytic at therapeutic doses, does not trigger psychosis or paranoia, good safety profile. CBD-dominant formulations are preferred for most mental health prescriptions.
• THC: Psychoactive, sleep-modulating — but at higher doses can cause or worsen anxiety, paranoia, and dissociation. High-THC products are used cautiously in mental health; dosing is typically started very low and titrated slowly.

Most UK mental health prescriptions involve CBD-dominant (high CBD:THC ratio) or balanced (1:1) formulations, with high-THC products reserved for specific presentations such as night-time PTSD symptom management under careful clinical monitoring.

UK Prescribing Practice and Monitoring

UK clinics prescribing for mental health conditions are expected to conduct a full psychiatric screening at initial consultation (including personal and family history of psychosis, bipolar disorder, substance use); start at low doses and titrate upward slowly; schedule follow-up appointments more frequently initially; monitor for adverse mental health outcomes; and discontinue or adjust if adverse effects emerge. If you are prescribed medical cannabis for a mental health condition, keep detailed notes of your symptoms and share them honestly at follow-up appointments.

Accessing Treatment

The process for accessing medical cannabis for a mental health condition is the same as for physical conditions — an initial video consultation with a GMC-registered specialist, a review of your medical history, and, if appropriate, a prescription. Costs range from £79 to £299 for an initial consultation. For a step-by-step overview, see our consultation guide and our NHS vs private guide.